[Tacrolimus administration to a patient with cyclosporine-induced encephalopathy after allogeneic bone marrow transplantation].
A 25-year-old woman with severe aplastic anemia received allogeneic bone marrow transplantation from an HLA-identical sibling. Pretransplant conditioning comprised 3.6 Gy of total body irradiation and 200 mg/kg cyclophosphamide. Cyclosporine (CSP) and methotrexate were administered to prevent graft-versus-host disease (GVHD). The patient complained of severe headache soon after CSP administration on day-1. On day 3, convulsion developed and she lost consciousness for 15 min. CT and MRI demonstrated low density areas and high signals, respectively, in the frontal and parietooccipital lobes and splenium of the corpus callosum, suggesting brain edema probably induced by CSP. After immediate withdrawal of CSP, glycerol and prednisolone were instituted, and the patient's condition improved. Thereafter, she developed grade II acute GVHD. This was treated with tacrolimus, which produced no adverse effects including central nervous system (CNS) toxicity. This case illustrates that careful management of CNS disorders induced by CSP can be important in patients undergoing allogeneic bone marrow transplantation.
Miyake
K
K
Kyushu University Graduate School of Medical Sciences.
Kamimura
T
T
Gondo
H
H
Okamura
T
T
Niho
Y
Y
D000328:Adult; D016026:Bone Marrow Transplantation; D001927:Brain Diseases / Q000139:chemically induced* / Q000188:drug therapy*; D016572:Cyclosporine / Q000009:adverse effects*; D005260:Female; D006086:Graft vs Host Disease / Q000517:prevention & control; D006801:Humans; D011183:Postoperative Complications; D016559:Tacrolimus / Q000627:therapeutic use*; D014184:Transplantation, Homologous
D016572:Cyclosporine; D016559:Tacrolimus